MX2020006594A - Inhibidores de exo-azaespiro de la interaccion menina-mll. - Google Patents

Inhibidores de exo-azaespiro de la interaccion menina-mll.

Info

Publication number
MX2020006594A
MX2020006594A MX2020006594A MX2020006594A MX2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A
Authority
MX
Mexico
Prior art keywords
menin
inhibitors
exo
aza spiro
mll interaction
Prior art date
Application number
MX2020006594A
Other languages
English (en)
Inventor
Patrick René Angibaud
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Wei Cai
Vineet Pande
Daniel Jason Krosky
Aaron Nathaniel Patrick
James Patrick Edwards
Xuedong Dai
Liqiang Fu
Linglong Kong
Yingtao Liu
Zhao - Kui WAN
Geb Herkert Barbara Morschhäuser
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020006594A publication Critical patent/MX2020006594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para terapia y/o profilaxis en un mamífero, composición farmacéutica que comprende dichos compuestos, y su uso como inhibidores de la interacción proteína/proteína menina/MLL, útiles para tratar enfermedades tales como cáncer, síndrome mielodisplásico (MDS) y diabetes.
MX2020006594A 2017-12-20 2018-12-19 Inhibidores de exo-azaespiro de la interaccion menina-mll. MX2020006594A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017117536 2017-12-20
CN2018091521 2018-06-15
PCT/CN2018/121960 WO2019120209A1 (en) 2017-12-20 2018-12-19 Exo-aza spiro inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
MX2020006594A true MX2020006594A (es) 2020-09-09

Family

ID=66993097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006594A MX2020006594A (es) 2017-12-20 2018-12-19 Inhibidores de exo-azaespiro de la interaccion menina-mll.

Country Status (12)

Country Link
US (1) US20230039917A1 (es)
EP (1) EP3728260A4 (es)
JP (1) JP7307729B2 (es)
KR (1) KR20200101389A (es)
CN (1) CN111601807B (es)
AU (1) AU2018389145B2 (es)
BR (1) BR112020012461A2 (es)
CA (1) CA3083624A1 (es)
IL (1) IL275457A (es)
MA (1) MA51337A (es)
MX (1) MX2020006594A (es)
WO (1) WO2019120209A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
CN110950818B (zh) * 2019-12-18 2021-12-28 浙江海翔药业股份有限公司 顺式-2,6-二甲基吗啉的纯化方法
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
BR112023021040A2 (pt) * 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AR125866A1 (es) * 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
MA40957A (fr) 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
US11396517B1 (en) * 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction

Also Published As

Publication number Publication date
MA51337A (fr) 2020-10-28
IL275457A (en) 2020-08-31
WO2019120209A1 (en) 2019-06-27
BR112020012461A2 (pt) 2020-11-24
AU2018389145A1 (en) 2020-05-21
US20230039917A1 (en) 2023-02-09
EP3728260A4 (en) 2021-08-11
RU2020123548A3 (es) 2022-02-17
CN111601807A (zh) 2020-08-28
RU2020123548A (ru) 2022-01-20
AU2018389145B2 (en) 2023-02-02
CA3083624A1 (en) 2019-06-27
CN111601807B (zh) 2023-03-31
JP2021506882A (ja) 2021-02-22
KR20200101389A (ko) 2020-08-27
JP7307729B2 (ja) 2023-07-12
EP3728260A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX389598B (es) Inhibidores bicíclicos condensados de la interacción de menina-mll.
MX392051B (es) Inhibidores espirobiciclicos de la interaccion de menina-mll
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
MX383213B (es) Inhibidores de tirosina-cinasas
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
EA201991448A1 (ru) Азепановые ингибиторы взаимодействия менин-mll
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
JOP20210128A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX391405B (es) Inhibidores de azepano de la interacción menina-mll.